Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study


The primary objective is to describe the effectiveness of dasatinib (Sprycel®) in CML patients in China in the real-world clinical practice setting.

Full Title of Study: “Effectiveness of Dasatinib(Sprycel®) in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: July 13, 2017

Detailed Description

Breakpoint cluster region (BCR) Abelson murine leukemia viral oncogene homolog 1 (c-ABL) Chronic myeloid leukemia (CML)


  • Drug: Dasatinib

Arms, Groups and Cohorts

  • CML patients treated with dasatinib
    • Cohort of chronic myeloid leukemia patients treated with second-line dasatinib (Sprycel)

Clinical Trial Outcome Measures

Primary Measures

  • Rate of Hematologic response (HR) for Chronic phase (CP), Advanced phase (AP),Blast phase (BP)
    • Time Frame: Upto 2 years
    • Hematological Response is a normalization of the blood counts, particularly white blood cell counts. This is the first noticeable indicator that treatment is beginning to work, though not necessarily in the bone marrow
  • Rate of Cytogenetic response (CR) for Chronic phase, Advanced phase,Blast phase
    • Time Frame: Upto 2 years
    • Cytogenetic Response is a response to treatment of CML that occurs in the marrow, rather than just in the blood
  • Rate of Molecular response (MR) for Chronic phase,Advanced phase,Blast phase
    • Time Frame: Upto 2 years
    • Molecular response is defined as no detectable BCR-ABL observed through Quantitative polymerase chain reaction (Q-PCR) (International Scale) using an assay with a sensitivity of at least 4.5 logs below the standardized baseline

Secondary Measures

  • Demographic and baseline characteristics of patients using dasatinib including health insurance, concomitant regimens, risk scores, and comorbidities based on patient-reported questionnaire
    • Time Frame: Upto 2 years
    • Type and percentage of each variable: health insurance, concomitant regimens and comorbidities; patients distribution by Sokal score
  • Dasatinib treatment pattern, including medication adherence and treatment interruption based on patient-reported questionnaire
    • Time Frame: Upto 2 years
    • Dasatinib starting dose and administration schedule, cumulative dose, maximum daily dose and duration of exposure; dose alterations (including changes in frequency, reductions and or delays) and reason(s) for dose alterations; discontinuation and reason(s) for dasatinib discontinuation
  • Relationship between time to initiation of dasatinib after imatinib failure and best response to dasatinib
    • Time Frame: Upto 2 years
  • Progression-free survival (PFS)
    • Time Frame: Upto 2 years
  • Overall survival (OS)
    • Time Frame: Upto 2 years
  • Safety of dasatinib measured by incidence and severity of adverse events
    • Time Frame: Upto 2 years

Participating in This Clinical Trial

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria:

Because this is a product registry study, it will include adult CML patients in any phase treated with dasatinib in China if they meet the following criteria:

  • Willing and able to provide written informed consent – ≥18 years of age – Confirmed diagnosis of CML patients by attending physician – Naive to dasatinib before enrollment in study treatment or have received <3 months of dasatinib treatment – Plan to or are receiving dasatinib therapy based on physician's clinical judgment – Administered dasatinib after imatinib-resistance or intolerance Exclusion Criteria:

  • Patients participating in clinical trials for CML that explicitly prohibit recruitment in additional studies

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bristol-Myers Squibb
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bristol-Myers Squibb, Study Director, Bristol-Myers Squibb

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.